GlaxoSmithKline (GSK) today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab,

[Suzym2u]

An investigational IL-5 antagonist, in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Churg Strauss Syndrome).

gsk.com/media/press-release...

[HiveMind]

Whoo Hoooo! Although I hope I never need it....fingers crossed. It's good to have as back up though.